MDxHealth (MDXH) Expected to Announce Quarterly Earnings on Wednesday

MDxHealth (NASDAQ:MDXH) is anticipated to release its earnings data after the market closes on Wednesday, February 26th. Analysts expect MDxHealth to post earnings of ($0.21) per share and revenue of $22.67 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

MDxHealth Trading Down 3.2 %

MDXH opened at $1.80 on Tuesday. MDxHealth has a fifty-two week low of $1.55 and a fifty-two week high of $3.85. The company has a market cap of $85.12 million, a price-to-earnings ratio of -1.18 and a beta of 1.34. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. The firm has a 50 day simple moving average of $2.03 and a 200 day simple moving average of $2.21.

Analyst Ratings Changes

MDXH has been the topic of a number of analyst reports. Lake Street Capital assumed coverage on MDxHealth in a research note on Thursday, October 31st. They issued a “buy” rating and a $7.00 price target on the stock. Piper Sandler dropped their price objective on MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Thursday, November 7th.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.